Login to Your Account



Financings Roundup

Synergy Offering to Bring in $90M for GI Drug Development

By Catherine Shaffer
Staff Writer

Thursday, April 11, 2013
Synergy Pharmaceuticals Inc., of New York, will boost its development of plecanatide, a candidate for gastrointestinal disorders, with an offering of $90 million of common stock. Plecanatide has the potential to treat disorders like chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription